Sponsors

Wellcome news for Agilent

Agilent Technologies has announced that the Wellcome Trust Case Control Consortium (WTCCC) will standardise the world’s largest human genomic copy number variation (CNV) study on Agilent microarrays. Agilent has also announced that IMGM Laboratories has achieved Certified Service Provider (CSP) status for the Agilent microarray platform.

The Wellcome Trust CNV study aims to determine the genetic causes of certain widespread diseases. The samples will be processed by Oxford Gene Technology (OGT), an Agilent microarray CSP in Oxford. This is an important study of human genetic variation in common diseases, which requires high-resolution microarrays with extremely reproducible performance.

IMGM is one of Europe’s leading genomic service providers and achieved Agilent-certified status after completing training and passing a rigorous series of assessments. These included demonstrating proficiency in, for example, analysing Agilent’s 60-mer oligo microarrays using the complete Agilent system, sample quality control using the Agilent 2100 bioanalyser, sample labelling using Agilent reagents and protocols, and final data analysis using the GeneSpring bioinformatics platform.

www. agilent.com

Latest Issues

BSMT 40th Anniversary Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025

Transforming Digital Pathology & AI: The Path Forward

Royal College Of Physicians Of Edinburgh
15 May, 2025

The 10 Year Plan - Clinical Innovations Expo

Jubilee Hotel and Conference Centre, Nottingham, UK
15 May, 2025